Hennigsdorf, 25 November 2015 – The Deutsche Biotech Innovativ AG (“DBI”) was able to generate gross proceeds of over 1.6 million Euros from its current capital increase. In total 48,938 new shares were placed at an issue price of 33.50 Euros. The new shares are expected to be delivered beginning of December 2015.
The proceeds from the capital increase will be invested in particular in the upcoming clinical development of the sepsis drug Adrecizumab which is developed by the project company Adrenomed AG.
“The financing market for biotech companies is difficult in Germany, in particular for young companies. With our first public offering we have therefore not achieved the desired goal, but nevertheless, we will push the further development of our pipeline – also with additional own resources”, says Dr. Bernd Wegener, CEO of DBI AG.
The application for the first-in-man clinical study with Adrecizumab is about to be submitted. In this study, the drug will be tested for its safety, tolerability and its effects on the human organism. The study is to be completed in 2016, so that the phase II study can follow directly afterwards in 20 to 30 clinical centers across Europe. The final results of the phase II study are expected by the end of 2018.
About Deutsche Biotech Innovativ AG
Deutsche Biotech Innovativ AG is a biotechnology company that uses innovative blood biomarkers to research and clinically develop unique therapies for serious diseases lacking adequate medical treatment options. Its focus is on drugs for sepsis and cancer. The company’s main product is Adrecizumab, a patented drug to reduce mortality due to organ failure in septic shock. Adrecizumab has successfully completed the preclinical phase and will be tested in a phase I study starting end of 2015.
DBI AG aims to further expand its drug pipeline and invest in the research and development of drugs with high unique-selling-point potential.
Both members of DBI AG’s Management Board, Dr Bernd Wegener and Dr. Andreas Bergmann, have many years of experience in the biotechnology field. Both were founders and part of the management team of B.R.A.H.M.S. AG, a highly successful biotechnology company specialized in blood biomarkers. It was sold in 2009 for around 330 million euro. Dr. Bernd Wegener is also a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie).
